利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.04 秒)

    Novel use of cannabinoid receptor agonist
    3.
    发明申请
    Novel use of cannabinoid receptor agonist 审中-公开
    新型使用大麻素受体激动剂

    公开(公告)号：US20070027144A1

    公开(公告)日：2007-02-01

    申请号：US10567754

    申请日：2004-08-16

    申请人： Akinori Arimura

    发明人： Akinori Arimura

    IPC分类号： A61K31/54

    CPC分类号： A61K31/435 ,  A61K31/5415 ,  C07D279/06

    摘要： An inhibitor for an inflammatory cell infiltration in the respiratory tract, an inhibitor for hyperirritability in the respiratory tract, a muciparous inhibitor, or a bronchodilator which contains as an active ingredient a compound represented by the formula (I) or (II): wherein R1 is the group represented by the formula: —C(=Z)-W—R4 wherein Z is an oxygen atom or the like; W is an oxygen atom or the like; R4 is optionally substituted alkyl or the like; R2 and R3 are independently optionally substituted alkyl or the like; or R2 and R3 are taken together to form optionally substituted alkylene which may contain a heteroatom(s); m is an integer of 0 to 2; A is optionally substituted aryl or optionally substituted heteroaryl; wherein R5 is the group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 and Y3 are each independently a bond or the like; Y2 is —C(═O)—NRb— or the like; Ra is optionally substituted alkyl, or the like; Rb is a hydrogen atom or the like; R6 is a hydrogen atom or the like; R7 and R8 are each independently optionally substituted alkyl or the like; or R7 and R8 are taken together with the adjacent carbon atoms to form a 5 to 8 membered ring which may contain a heteroatom(s) and/or an unsaturated bond(s); R9 is optionally substituted alkyl which may contain a heteroatom(s) and/or an unsaturated bond(s), or the like; X is a oxygen atom or the like.

    摘要翻译： 用于呼吸道炎症细胞浸润的抑制剂，呼吸道中的高刺激性抑制剂，粘液抑制剂或支气管扩张剂，其含有由式（I）或（II）表示的化合物作为活性成分：其中R 其中Z为氧原子等;其中Z为氧原子等;其中Z为氧原子等;其中Z为氧原子等; W是氧原子等; R 4是任选取代的烷基等; R 2和R 3独立地是任选取代的烷基等; 或R 2和R 3一起形成任选取代的可含有杂原子的亚烷基; m为0〜2的整数; A是任选取代的芳基或任选取代的杂芳基; 其中R 5为由下式表示的基团：-Y 1 -Y 2 -Y 3 -R 其中Y 1和Y 3各自独立地为键或类似物; Y 2是-C（-O）-NR B 2 - 等; R a是任选取代的烷基等; R b是氢原子等; R 6是氢原子等; R 7和R 8各自独立地是任选取代的烷基等; 或R 7和R 8与相邻的碳原子一起形成可含有杂原子和/或不饱和键的5至8元环 （s）; R 9是可以含有杂原子和/或不饱和键的任选取代的烷基等; X是氧原子等。

    Th2 differentiation inhibitors
    4.
    发明授权
    Th2 differentiation inhibitors 失效
    Th2分化抑制剂

    公开(公告)号：US07008954B1

    公开(公告)日：2006-03-07

    申请号：US09980475

    申请日：2000-07-14

    申请人： Akinori Arimura ,  Kenji Kawada

    发明人： Akinori Arimura ,  Kenji Kawada

    IPC分类号： A61K31/09 ,  A61K31/136 ,  A61K31/15

    CPC分类号： C07C251/58 ,  A61K31/05 ,  A61K31/075 ,  A61K31/095 ,  A61K31/135 ,  A61K31/136 ,  A61K31/15 ,  A61K31/235 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  C07C211/50 ,  C07C217/80

    摘要： The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (I): wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a single bond, —O—, —CH2—, —NH—, —SO— and the like, Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl and the like, each of V1 and V2 is a single bond, —O—, —NH—, —OCH2— and the like, a prodrug, pharmaceutically acceptable salt or solvate thereof.

    摘要翻译： 本发明提供一种用作Th2分化抑制剂的药物组合物，其包含由式（I）表示的化合物：其中环A，环B和环C各自为芳族碳环，杂环等，X为 单键，-O-，-CH 2 - ， - NH - ， - SO-等，Y是氢，任选取代的低级烷基，任选取代的低级烯基等， V 1和V 2是单键，-O - ， - NH - ， - OCH 2 - 等，前药， 其药学上可接受的盐或溶剂合物。

    Drug composition antagonistic to both PGD2/TXA2 receptors
    6.
    发明授权
    Drug composition antagonistic to both PGD2/TXA2 receptors 失效
    与PGD2 / TXA2受体拮抗的药物组合物

    公开(公告)号：US07084136B2

    公开(公告)日：2006-08-01

    申请号：US10297065

    申请日：2001-05-28

    申请人： Norihiko Tanimoto ,  Akinori Arimura

    发明人： Norihiko Tanimoto ,  Akinori Arimura

    IPC分类号： A61K31/535 ,  A61K31/40 ,  C07D417/00 ,  C07D209/02 ,  C07D333/78

    CPC分类号： C07D333/38

    摘要： A compound of the formula (I): wherein A is alkylene optionally having an unsaturated bond; R is —C(═O)—R1; R1 is hydroxy or the like; m is 0 or 1; p is 0 or 1; X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl or the like; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(═O)—, or the like, having a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor is found.

    摘要翻译： 式（I）的化合物：其中A是任选具有不饱和键的亚烷基; R是-C（-O）-R 1; R 1是羟基等; m为0或1; p为0或1; X 1和X 3各自独立地是任选取代的芳基或任选取代的杂芳基等; X 2是一个键，-CH 2 - ， - S - ， - SO 2 - ， - CH 2 ，-O-CH 2 - ， - CH 2 -S-，-S-CH 2 - 等 ; X 4是-CH 2 - ， - CH 2 -CH 2 - ， - C（ - O） 发现具有针对血栓素A 2 O 2受体和前列腺素D 2受体的双重拮抗活性的 - 等等。